Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -6 of 6 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Clinical and Molecular-Metabolic Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 222 NCT00400920


2.		A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosne 228 NCT00448721


3.		Ph II Study of Perifosine for Patients With Carcinoma of the Kidney

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Pharmaceutical / Industry				Perifosine 231 NCT00498966

Last Modified: 6/4/2007 First Published: 3/3/2006


4.		Phase I Study of UCN-01 in Combination With Perifosine in Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or High Risk Myelodysplastic Syndromes

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				NCI				MSGCC-0507 MSGCC-H-27229-0507, NCI-7311, 7311, NCT00301938


5.		Perifosine and Docetaxel in Patients With Relapsed Epithelial Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Treatment				Active				18 and over				Other				2004-0970 NCT00431054


6.		Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and under				Other				08-091 NCT00776867

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute